Development and validation of a gene expression-based Breast Cancer Purity Score.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
20
03
2024
accepted:
06
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
The prevalence of malignant cells in clinical specimens, or tumour purity, is affected by both intrinsic biological factors and extrinsic sampling bias. Molecular characterization of large clinical cohorts is typically performed on bulk samples; data analysis and interpretation can be biased by tumour purity variability. Transcription-based strategies to estimate tumour purity have been proposed, but no breast cancer specific method is available yet. We interrogated over 6000 expression profiles from 10 breast cancer datasets to develop and validate a 9-gene Breast Cancer Purity Score (BCPS). BCPS outperformed existing methods for estimating tumour content. Adjusting transcriptomic profiles using the BCPS reduces sampling bias and aids data interpretation. BCPS-estimated tumour purity improved prognostication in luminal breast cancer, correlated with pathologic complete response in on-treatment biopsies from triple-negative breast cancer patients undergoing neoadjuvant treatment and effectively stratified the risk of relapse in HER2+ residual disease post-neoadjuvant treatment.
Identifiants
pubmed: 39448787
doi: 10.1038/s41698-024-00730-7
pii: 10.1038/s41698-024-00730-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
242Investigateurs
Luca Gianni
(L)
Giancarlo Bisagni
(G)
Marco Colleoni
(M)
Lucia Del Mastro
(L)
Claudio Zamagni
(C)
Mauro Mansutti
(M)
Milvia Zambetti
(M)
Antonio Frassoldati
(A)
Luca Gianni
(L)
Filippo Montemurro
(F)
Claudio Zamagni
(C)
Lucia Del Mastro
(L)
Carmelo Bengala
(C)
Marco Colleoni
(M)
Gabriella Mariani
(G)
Anna Gambaro
(A)
Stefania Zambelli
(S)
Giampaolo Bianchini
(G)
Giancarlo Bisagni
(G)
Stefania Russo
(S)
Chiun-Sheng Huang
(CS)
Shou-Tung Chen
(ST)
Ming Feng Hou
(MF)
Liang-Chih Liu
(LC)
Ling Ming Tseng
(LM)
Catherine Kelly
(C)
Seamus O'Reilly
(S)
Patrick Morris
(P)
John Kennedy
(J)
Miriam O'Connor
(M)
Richard Greil
(R)
Daniel Egle
(D)
Mark Thill
(M)
Jacqueline Sagasser
(J)
Gerd Graffunder
(G)
Dirk Behringer
(D)
Hans Tesch
(H)
Hans-Joachim Lück
(HJ)
Andreas Schneeweiss
(A)
Claudia Schumacher
(C)
Wolfram Malter
(W)
Vladimir Semiglazov
(V)
Mona Frolova
(M)
Alexander Vasiliev Gennadievich
(AV)
Nikita Volkov
(N)
Begoña Bermejo
(B)
Catalina Falo
(C)
Elena Sevillano
(E)
Eva Maria Ciruelos Gil
(EM)
José Ángel García Sáenz
(JÁ)
Anton Antón-Torres
(A)
Informations de copyright
© 2024. The Author(s).
Références
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346–354 (2013).
doi: 10.1038/nature12626
pubmed: 24048067
Lou, S. et al. Comprehensive Characterization of Tumor Purity and Its Clinical Implications in Gastric Cancer. Front Cell Dev. Biol. 9, 3843 (2022).
doi: 10.3389/fcell.2021.782529
Zhang, C. et al. Tumor purity as an underlying key factor in glioma. Clin. Cancer Res. 23, 6279–6291 (2017).
doi: 10.1158/1078-0432.CCR-16-2598
pubmed: 28754819
Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 8971 (2015).
doi: 10.1038/ncomms9971
pubmed: 26634437
Haider, S. et al. Systematic Assessment of Tumor Purity and Its Clinical Implications. JCO Precis Oncol. 4, 995–1005 (2020).
doi: 10.1200/PO.20.00016
Fisher, N. C. et al. Biological Misinterpretation of Transcriptional Signatures in Tumor Samples can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clin. Cancer Res. 28, OF1–OF14 (2022).
doi: 10.1158/1078-0432.CCR-22-1102
Rhee, J. K. et al. Impact of tumor purity on immune gene expression and clustering analyses across multiple cancer types. Cancer Immunol. Res. 6, 87–97 (2018).
doi: 10.1158/2326-6066.CIR-17-0201
pubmed: 29141981
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
doi: 10.1038/nbt.2203
pubmed: 22544022
pmcid: 4383288
van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
doi: 10.1073/pnas.1009843107
pubmed: 20837533
pmcid: 2947907
Bernard, P. S. et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J. Clin. Oncol. 27, 1160 (2009).
doi: 10.1200/JCO.2008.18.1370
pubmed: 19204204
pmcid: 2667820
Sparano, J. A. et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N. Engl. J. Med. 380, 2395–2405 (2019).
doi: 10.1056/NEJMoa1904819
pubmed: 31157962
pmcid: 6709671
Callari, M. et al. Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin. Cancer Res. 22, 337–345 (2016).
doi: 10.1158/1078-0432.CCR-15-0757
pubmed: 26423797
Park, Y. H., et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, https://doi.org/10.1038/s41467-020-19933-0 (2020).
Smits, A. J. J. et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod. Pathol. 27, 168–174 (2014).
doi: 10.1038/modpathol.2013.134
pubmed: 23887293
Anghel, C. v. et al. ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles. BMC Bioinformatics 16, https://doi.org/10.1186/S12859-015-0597-X (2015).
Ahn, J. et al. DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics 29, 1865–1871 (2013).
doi: 10.1093/bioinformatics/btt301
pubmed: 23712657
pmcid: 3841439
Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 1–11 (2013).
doi: 10.1038/ncomms3612
Gianni, L. et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 19, 249–256 (2018).
doi: 10.1016/S1470-2045(18)30001-9
pubmed: 29326029
Gianni, L. et al. Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. NPJ Breast Cancer 8, https://doi.org/10.1038/s41523-021-00377-8 (2022).
Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2022.02.004 (2022).
Bianchini, G. et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann. Oncol. 26, 2429–2436 (2015).
doi: 10.1093/annonc/mdv395
pubmed: 26387142
Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat. Genet 45, 1113 (2013).
doi: 10.1038/ng.2764
pubmed: 24071849
pmcid: 3919969
Bruna, A. et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell 167, 260–274.e22 (2016).
doi: 10.1016/j.cell.2016.08.041
pubmed: 27641504
pmcid: 5037319
Metzger-Filho, O. et al. Genomic grade adds prognostic value in invasive lobular carcinoma. Ann. Oncol. 24, 377–384 (2013).
doi: 10.1093/annonc/mds280
pubmed: 23028037
Foroutan, M. et al. Single sample scoring of molecular phenotypes. BMC Bioinforma. 19, 1–10 (2018).
doi: 10.1186/s12859-018-2435-4
Brueffer, C. et al. Clinical Value of RNA Sequencing-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network-Breast Initiative. JCO Precis. Oncology 2, 1–18 (2018).
Bianchini, G. et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J. Clin. Oncol. 28, 4316–4323 (2010).
doi: 10.1200/JCO.2009.27.2419
pubmed: 20805453
Jimenez-Sanchez, A., Cast, O. & Miller, M. L. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 79, 6238–6246 (2019).
doi: 10.1158/0008-5472.CAN-18-3560
pubmed: 31641033
Symmans, W. F. et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J. Clin. Oncol. 35, 1049–1060 (2017).
doi: 10.1200/JCO.2015.63.1010
pubmed: 28135148
pmcid: 5455352
Quon, G. et al. Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. Genome Med. 5, 29 (2013).
doi: 10.1186/gm433
pubmed: 23537167
pmcid: 3706990
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
doi: 10.1038/nature10983
pubmed: 22522925
pmcid: 3440846